IL132918A - Pharmacological formulations containing vericonazole and a derivative of cyclodextrin - Google Patents

Pharmacological formulations containing vericonazole and a derivative of cyclodextrin

Info

Publication number
IL132918A
IL132918A IL13291898A IL13291898A IL132918A IL 132918 A IL132918 A IL 132918A IL 13291898 A IL13291898 A IL 13291898A IL 13291898 A IL13291898 A IL 13291898A IL 132918 A IL132918 A IL 132918A
Authority
IL
Israel
Prior art keywords
formulation
voriconazole
cyclodextrin
cyclodextrin derivative
derivative
Prior art date
Application number
IL13291898A
Other languages
English (en)
Hebrew (he)
Other versions
IL132918A0 (en
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10814734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL132918(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of IL132918A0 publication Critical patent/IL132918A0/xx
Publication of IL132918A publication Critical patent/IL132918A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL13291898A 1997-06-21 1998-06-02 Pharmacological formulations containing vericonazole and a derivative of cyclodextrin IL132918A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9713149.4A GB9713149D0 (en) 1997-06-21 1997-06-21 Pharmaceutical formulations
PCT/EP1998/003477 WO1998058677A1 (en) 1997-06-21 1998-06-02 Pharmaceutical formulations containing voriconazole

Publications (2)

Publication Number Publication Date
IL132918A0 IL132918A0 (en) 2001-03-19
IL132918A true IL132918A (en) 2001-09-13

Family

ID=10814734

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13291898A IL132918A (en) 1997-06-21 1998-06-02 Pharmacological formulations containing vericonazole and a derivative of cyclodextrin

Country Status (48)

Country Link
US (1) US6632803B1 (de)
EP (1) EP1001813B8 (de)
JP (2) JP2000513029A (de)
KR (1) KR100372988B1 (de)
CN (1) CN1125653C (de)
AP (1) AP912A (de)
AR (1) AR015900A1 (de)
AT (1) ATE238812T1 (de)
AU (1) AU724799B2 (de)
BG (1) BG64584B1 (de)
BR (1) BRPI9809468B8 (de)
CA (1) CA2295035C (de)
CO (1) CO4940450A1 (de)
CZ (1) CZ289570B6 (de)
DE (1) DE69814091T2 (de)
DK (1) DK1001813T3 (de)
DZ (1) DZ2523A1 (de)
EA (1) EA001924B1 (de)
EG (1) EG23910A (de)
ES (1) ES2195355T3 (de)
GB (1) GB9713149D0 (de)
HK (1) HK1027966A1 (de)
HR (1) HRP980341B1 (de)
HU (1) HU228338B1 (de)
ID (1) ID22939A (de)
IL (1) IL132918A (de)
IS (1) IS2004B (de)
MA (1) MA26508A1 (de)
ME (1) ME00907B (de)
MY (1) MY118151A (de)
NO (1) NO313125B1 (de)
NZ (1) NZ501066A (de)
OA (1) OA11232A (de)
PA (1) PA8453201A1 (de)
PE (1) PE84899A1 (de)
PL (1) PL191295B1 (de)
PT (1) PT1001813E (de)
RS (1) RS49633B (de)
SA (1) SA98190159B1 (de)
SI (1) SI1001813T1 (de)
SK (1) SK282946B6 (de)
TN (1) TNSN98090A1 (de)
TR (1) TR199903191T2 (de)
TW (1) TW406023B (de)
UA (1) UA57083C2 (de)
UY (1) UY25055A1 (de)
WO (1) WO1998058677A1 (de)
ZA (1) ZA985364B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9818258D0 (en) * 1998-08-21 1998-10-14 Pfizer Ltd Antifungal compositions
PE20020300A1 (es) 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
AR031135A1 (es) 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
WO2004017897A2 (en) 2002-08-20 2004-03-04 Bristol-Myers Squibb Company Aripiprazole complex formulation and method
GB0327390D0 (en) * 2003-11-25 2003-12-31 Pfizer Ltd Pharmaceutical formulations
EP1691801A4 (de) * 2003-12-08 2009-12-09 Univ Arizona State Synergistische anti-krebs-zusammensetzungen
CA2572223C (en) 2004-06-25 2014-08-12 The Johns Hopkins University Angiogenesis inhibitors
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
US20070082870A1 (en) * 2005-10-11 2007-04-12 Buchanan Charles M Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
AR061889A1 (es) 2006-07-13 2008-10-01 Medichem Sa Proceso mejorado para la preparacion de voriconazol
CN1919846B (zh) * 2006-09-14 2013-01-02 大道隆达（北京）医药科技发展有限公司 伏立康唑及其药用盐、中间体的一种新定向合成制备方法
BG1110U1 (bg) * 2007-06-19 2008-09-30 Рудолф ПОДЛИПСКИ Отоплителен съд за експресно локално загряване навода
EP2018866A1 (de) * 2007-07-27 2009-01-28 Sandoz AG Pharmazeutische Zusammensetzungen mit Voriconazol
US8192721B2 (en) * 2007-12-13 2012-06-05 Verrow Pharmaceuticals, Inc. Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
WO2009137611A2 (en) * 2008-05-06 2009-11-12 Board Of Regents, The University Of Texas System Treatment of pulmonary fungal infection with voriconazole via inhalation
EP2303265B1 (de) * 2008-06-06 2014-12-10 Glenmark Pharmaceuticals Limited Stabile topische formulierung mit voriconazol
CN101390825B (zh) * 2008-10-01 2010-12-29 山东省眼科研究所 一种伏立康唑眼内释药系统
EP3090737A1 (de) 2008-10-21 2016-11-09 Onyx Therapeutics, Inc. Kombinationstherapie mit peptidepoxyketonen
CN101444510B (zh) * 2008-12-31 2011-03-09 南京卡文迪许生物工程技术有限公司 含有伏立康唑的药物制剂及其制备方法
EA201270283A1 (ru) 2009-08-19 2012-12-28 Рациофарм Гмбх Способ получения соэвапоратов и комплексы, содержащие вориконазол и циклодекстрин
WO2011064558A2 (en) 2009-11-30 2011-06-03 Cipla Limited Pharmaceutical composition
EP2588116A4 (de) 2010-06-29 2013-12-04 Merck Sharp & Dohme Durch substituiertes beta-cyclodextrin stabilisierte intravenöse posaconazollösungsformulierungen
EP2409699B1 (de) 2010-07-23 2014-04-30 Combino Pharm, S.L. Stabile Voriconazole-enthaltende Zusammensetzungen
CN102058519B (zh) * 2010-11-19 2013-01-02 苏州特瑞药业有限公司 一种伏立康唑缓释栓剂及其制备方法
KR101731155B1 (ko) 2011-06-15 2017-04-27 신톤 비.브이. 안정화된 보리코나졸 조성물
EP2561863A1 (de) 2011-08-22 2013-02-27 Farmaprojects, S.A.U. Pharmazeutische Zusammensetzungen mit Voriconazol
WO2013103924A2 (en) * 2012-01-05 2013-07-11 Guilford Frederick Timothy Liposomally encapsulated reduced glutathione for management of cancer, including with other pharmaceutical compositions
US8853248B2 (en) 2012-04-05 2014-10-07 Hubert Maehr (1,2,3-triazolyl)sulfonyl derivatives
KR20200130748A (ko) 2012-05-08 2020-11-19 오닉스 세라퓨틱스, 인크. 펩티드 프로테아좀 억제제 제제화를 위한 사이클로덱스트린 복합체화 방법
AU2013257830A1 (en) 2012-05-11 2014-11-20 Cipla Limited Pharmaceutical composition
US20150352112A1 (en) 2013-01-11 2015-12-10 Xellia Pharmaceuticals Aps Voriconazole inclusion complexes
CA2904670A1 (en) 2013-03-14 2014-09-13 Fresenius Kabi Usa, Llc Voriconazole formulations
GB201312737D0 (en) 2013-07-17 2013-08-28 Univ Greenwich Cyclodextrin
CN103690968A (zh) * 2013-11-21 2014-04-02 石药集团中奇制药技术（石家庄）有限公司 一种伏立康唑组合物及其制备方法
PT109117B (pt) * 2016-01-28 2019-02-01 Hovione Farm Sa Complexação de ingredientes ativos farmacêuticos
CN110022857A (zh) 2016-11-18 2019-07-16 艾库里斯抗感染治疗有限公司 基于改性环糊精和酸化剂的脒取代β-内酰胺化合物的新制剂、其制备及作为抗微生物药物组合物的用途
EP3584245A4 (de) * 2017-02-17 2020-08-26 Wuhan LL Science And Technology Development Co., Ltd. Antibakterielles derivat aus triazol sowie pharmazeutische zusammensetzung und verwendung davon
CN113750034A (zh) * 2020-06-05 2021-12-07 中南大学湘雅三医院 耳用温敏凝胶及其制备方法
CN116570558B (zh) * 2023-06-21 2023-12-26 广州仁恒医药科技股份有限公司 一种伏立康唑眼用纳米缓释组合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
DE3347421A1 (de) 1983-12-29 1985-07-11 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von fluorarmen alkaliphosphatloesungen
GB8819308D0 (en) 1988-08-13 1988-09-14 Pfizer Ltd Triazole antifungal agents
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9002375D0 (en) * 1990-02-02 1990-04-04 Pfizer Ltd Triazole antifungal agents
US5278175A (en) * 1990-02-02 1994-01-11 Pfizer Inc. Triazole antifungal agents
GB9512961D0 (en) 1995-06-26 1995-08-30 Pfizer Ltd Antifungal agents
GB9602080D0 (en) 1996-02-02 1996-04-03 Pfizer Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
HUP0003323A3 (en) 2002-01-28
EP1001813B1 (de) 2003-05-02
BR9809468A (pt) 2000-06-20
UY25055A1 (es) 2000-12-29
YU68199A (sh) 2002-06-19
CO4940450A1 (es) 2000-07-24
SI1001813T1 (en) 2004-02-29
US6632803B1 (en) 2003-10-14
EA199900937A1 (ru) 2000-08-28
AR015900A1 (es) 2001-05-30
CZ289570B6 (cs) 2002-02-13
DZ2523A1 (fr) 2003-02-01
BG103882A (en) 2000-07-31
PE84899A1 (es) 1999-09-17
EA001924B1 (ru) 2001-10-22
IS5248A (is) 1999-11-15
HRP980341A2 (en) 1999-02-28
TW406023B (en) 2000-09-21
WO1998058677A1 (en) 1998-12-30
NO313125B1 (no) 2002-08-19
PT1001813E (pt) 2003-07-31
NO995565L (no) 1999-11-30
JP2002332234A (ja) 2002-11-22
ES2195355T3 (es) 2003-12-01
DE69814091T2 (de) 2004-01-22
CN1261287A (zh) 2000-07-26
HK1027966A1 (en) 2001-02-02
PA8453201A1 (es) 2000-05-24
CA2295035A1 (en) 1998-12-30
JP5089004B2 (ja) 2012-12-05
EG23910A (en) 2007-12-30
AU724799B2 (en) 2000-09-28
SK159399A3 (en) 2000-06-12
JP2000513029A (ja) 2000-10-03
AU8110498A (en) 1999-01-04
HRP980341B1 (en) 2001-12-31
BG64584B1 (bg) 2005-08-31
SA98190159B1 (ar) 2005-12-21
EP1001813B8 (de) 2014-02-12
PL191295B1 (pl) 2006-04-28
CN1125653C (zh) 2003-10-29
PL337692A1 (en) 2000-08-28
ID22939A (id) 1999-12-16
ME00907B (me) 2007-08-03
BRPI9809468B8 (pt) 2022-01-18
DE69814091D1 (de) 2003-06-05
OA11232A (en) 2003-05-26
DK1001813T3 (da) 2003-07-28
IL132918A0 (en) 2001-03-19
MA26508A1 (fr) 2004-12-20
GB9713149D0 (en) 1997-08-27
NZ501066A (en) 2001-01-26
UA57083C2 (uk) 2003-06-16
IS2004B (is) 2005-04-15
EP1001813A1 (de) 2000-05-24
CZ409699A3 (cs) 2000-02-16
ATE238812T1 (de) 2003-05-15
KR20010014006A (ko) 2001-02-26
AP912A (en) 2001-12-08
CA2295035C (en) 2005-04-19
BR9809468B1 (pt) 2013-11-12
NO995565D0 (no) 1999-11-12
HU228338B1 (en) 2013-03-28
ZA985364B (en) 1999-12-20
TNSN98090A1 (fr) 2005-03-15
AP9801268A0 (en) 1998-06-30
TR199903191T2 (xx) 2000-09-21
KR100372988B1 (ko) 2003-02-25
SK282946B6 (sk) 2003-01-09
HUP0003323A2 (hu) 2001-06-28
MY118151A (en) 2004-09-30
RS49633B (sr) 2007-08-03

Similar Documents

Publication Publication Date Title
AP912A (en) Pharmaceutical-formulations containing voriconazole.
KR100451485B1 (ko) 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
AU2003234285B2 (en) Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
EP0216362A2 (de) Stabile gefriergetrocknete Zubereitungen eines gegen Krebs wirksamen Platinkomplexes
IE80461B1 (en) New compositions containing taxane derivatives
US11730815B2 (en) Stable liquid pharmaceutical compositions comprising bendamustine
MXPA04012426A (es) Preparacion liquida que contiene oligopeptidos.
US11986486B2 (en) Aqueous compositions of bortezomib
MXPA99012075A (en) Pharmaceutical formulations containing voriconazole
WO2001047542A1 (fr) Preparations de vancomycine
CA2486571C (en) Pharmaceutical composition
NL8803126A (nl) Waterige preparaten die een piperidinylcyclopentylhepteenzuurderivaat bevatten.

Legal Events

Date Code Title Description
KB20 Patent renewed for 20 years
EXP Patent expired